The world had fairly high expectations for Biogen and Eisai’s latest clinical trial on Alzheimer’s disease, and the data, revealed Wednesday, seemed to exceed them. So why is Biogen now worth $7 billion less than it was 24 hours ago?

That’s the conversation reverberating around biotech Thursday, and the answer boils down confusion about patient groups and, of course, renewed skepticism of the amyloid hypothesis.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy